82 related articles for article (PubMed ID: 14764750)
1. Biochemical monitoring of disease activity after surgery for acromegaly.
Shalet SM
J Clin Endocrinol Metab; 2004 Feb; 89(2):492-4. PubMed ID: 14764750
[No Abstract] [Full Text] [Related]
2. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society.
;
J Clin Endocrinol Metab; 2004 Jul; 89(7):3099-102. PubMed ID: 15240576
[No Abstract] [Full Text] [Related]
3. Letter re: Monitoring the response to treatment in acromegaly.
Ayuk J; Sheppard MC; Bates AS; Stewart PM
J Clin Endocrinol Metab; 2005 Aug; 90(8):4980. PubMed ID: 16087964
[No Abstract] [Full Text] [Related]
4. The role of insulin-like growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery.
Wu TE; Lin HD; Lu RA; Wang ML; Chen RL; Chen HS
Growth Horm IGF Res; 2010 Dec; 20(6):411-5. PubMed ID: 20943425
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of radiotherapy in acromegaly.
González B; Vargas G; Espinosa-de-los-Monteros AL; Sosa E; Mercado M
Arch Med Res; 2011 Jan; 42(1):48-52. PubMed ID: 21376263
[TBL] [Abstract][Full Text] [Related]
6. The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly.
Karavitaki N; Fernandez A; Fazal-Sanderson V; Wass JA
Clin Endocrinol (Oxf); 2009 Dec; 71(6):840-5. PubMed ID: 19320648
[TBL] [Abstract][Full Text] [Related]
7. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
[TBL] [Abstract][Full Text] [Related]
8. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
Serri O; Beauregard C; Hardy J
J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
[TBL] [Abstract][Full Text] [Related]
9. Current diagnostic guidelines for biochemical diagnosis of acromegaly.
Ferone D; Resmini E; Bocca L; Giusti M; Barreca A; Minuto F
Minerva Endocrinol; 2004 Dec; 29(4):207-23. PubMed ID: 15765030
[TBL] [Abstract][Full Text] [Related]
10. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice.
Bielohuby M; Roemmler J; Manolopoulou J; Johnsen I; Sawitzky M; Schopohl J; Reincke M; Wolf E; Hoeflich A; Bidlingmaier M
Exp Biol Med (Maywood); 2009 Aug; 234(8):1002-9. PubMed ID: 19491373
[TBL] [Abstract][Full Text] [Related]
11. Excessively high soluble Klotho in patients with acromegaly.
Sze L; Bernays RL; Zwimpfer C; Wiesli P; Brändle M; Schmid C
J Intern Med; 2012 Jul; 272(1):93-7. PubMed ID: 22452701
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
Freda PU; Post KD; Powell JS; Wardlaw SL
J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
[TBL] [Abstract][Full Text] [Related]
13. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status.
Espinosa-de-Los-Monteros AL; Sosa E; Cheng S; Ochoa R; Sandoval C; Guinto G; Mendoza V; Hernández I; Molina M; Mercado M
Clin Endocrinol (Oxf); 2006 Mar; 64(3):245-9. PubMed ID: 16487431
[TBL] [Abstract][Full Text] [Related]
14. Predictors of outcome following Gamma Knife surgery for acromegaly.
Poon TL; Leung SC; Poon CY; Yu CP
J Neurosurg; 2010 Dec; 113 Suppl():149-152. PubMed ID: 21222293
[TBL] [Abstract][Full Text] [Related]
15. [Somatostatin agonists in the treatment of acromegaly].
Jaquet P; Morange-Rahos I; Janano B; Moati P; Brue T
Ann Endocrinol (Paris); 1998 Nov; 59(4):301-4. PubMed ID: 9864550
[No Abstract] [Full Text] [Related]
16. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
17. Editorial: acromegaly--consensus, what consensus?
Trainer PJ
J Clin Endocrinol Metab; 2002 Aug; 87(8):3534-6. PubMed ID: 12161470
[No Abstract] [Full Text] [Related]
18. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
[TBL] [Abstract][Full Text] [Related]
19. Acromegaly surgery in Manchester revisited--the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission.
Wang YY; Higham C; Kearney T; Davis JR; Trainer P; Gnanalingham KK
Clin Endocrinol (Oxf); 2012 Mar; 76(3):399-406. PubMed ID: 21824170
[TBL] [Abstract][Full Text] [Related]
20. The role of elevated growth hormone on the increased atherosclerosis in patients with acromegaly.
Rizzo M; Montalto G; Rizvi AA; Christ ER
Angiology; 2012 Oct; 63(7):492-4. PubMed ID: 22371625
[No Abstract] [Full Text] [Related]
[Next] [New Search]
